secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0000950170-23-059812
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus Q3 net loss $10.1M; pipeline progress with CRB-701, CRB-601, CRB-913
---------------------------------------------------------------------------

- Net loss of $10.1M ($2.27 per diluted share) vs $8.8M ($2.11) in Q3 2022.
- Cash, equivalents, and investments of $28.7M as of Sept 30, 2023.
- CRB-701 Phase 1 dose escalation ongoing; early clinical data expected Q1 2024 alongside U.S./EU trial start.
- IND submission for CRB-601 on track for Q4 2023; pre-clinical data presented at SITC.
- CRB-913 pre-clinical study published in Obesity; shows no lean muscle loss when combined with incretins.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000095017023059812/0000950170-23-059812-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000095017023059812/crbp-20231107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-059812

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer